P-052 - A PHASE 1 STUDY COMPARING THE PHARMACOKINETICS, SAFETY AND IMMUNOGENICITY BETWEEN HLX12, A PROPOSED RAMUCIRUMAB BIOSIMILAR, WITH REFERENCE RAMUCIRUMAB IN HEALTHY CHINESE MALES.
Y. Ding1, X. Dong2, L. Zhou2, W. Kang2, J. Zhu2; 1The First Hospital of Jilin University, Changchun, China, 2Shanghai Henlius Biotech, Inc., Shanghai, China.
.jpg "Yanhua Ding, MD, PhD photo")
.png)